 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for ZNF165 |
 Gene summary |
| Basic gene information | Gene symbol | ZNF165 |
| Gene name | zinc finger protein 165 | |
| Synonyms | CT53|LD65|ZSCAN7 | |
| Cytomap | UCSC genome browser: 6p21.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_003447.3, | |
| Description | cancer/testis antigen 53zinc finger and SCAN domain-containing protein 7 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 600834 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000197279 | ||
| HPRD : 02903 | ||
| Vega : OTTHUMG00000014505 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_ZNF165 | |
| BioGPS: 7718 | ||
| Pathway | NCI Pathway Interaction Database: ZNF165 | |
| KEGG: ZNF165 | ||
| REACTOME: ZNF165 | ||
| Pathway Commons: ZNF165 | ||
| Context | iHOP: ZNF165 | |
| ligand binding site mutation search in PubMed: ZNF165 | ||
| UCL Cancer Institute: ZNF165 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
| Reference showing the relevant tissue of ZNF165 | ||
| Description by TissGene annotations | TissgsLTS | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for ZNF165 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| KIRP | -1.434788906 | -0.174667031 | -1.260121875 | 8.03E-11 | 9.43E-10 |
| KIRC | -1.508650364 | -0.325483697 | -1.183166667 | 1.80E-21 | 1.57E-20 |
| KICH | 0.918884969 | -0.123655031 | 1.04254 | 0.00114 | 0.002444125 |
| Top |
| TissGene-miRNA for ZNF165 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for ZNF165 |
| TissGeneSNV for ZNF165 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.S325P | LGG | 1 |
| p.E240K | SKCM | 1 |
| p.H418R | OV | 1 |
| p.R364T | HNSC | 1 |
| p.W303C | HNSC | 1 |
| p.E111V | KIRC | 1 |
| p.E65K | SKCM | 1 |
| p.E17* | BLCA | 1 |
| p.E111* | LUAD | 1 |
| p.E376K | BLCA | 1 |
| p.K257R | STAD | 1 |
| p.G378E | BLCA | 1 |
| p.Q50R | LGG | 1 |
| p.L443H | LIHC | 1 |
| p.N375Y | SKCM | 1 |
| p.D341N | LUSC | 1 |
| p.R206I | UCEC | 1 |
| p.M193I | UCEC | 1 |
| p.N375S | SKCM | 1 |
| p.T122I | COAD | 1 |
| p.A230V | STAD | 1 |
| p.Y456N | STAD | 1 |
| p.E26X | COAD | 1 |
| p.E197K | SKCM | 1 |
| p.E369D | BRCA | 1 |
| p.E376K | LUAD | 1 |
| p.I477L | PRAD | 1 |
| p.T122N | CHOL | 1 |
| p.P61A | CESC | 1 |
| p.E376D | STAD | 1 |
| p.Q345H | LUSC | 1 |
| p.E186Q | BLCA | 1 |
| p.R391W | COAD | 1 |
| p.D386H | UCEC | 1 |
| p.L484I | SKCM | 1 |
| p.K318T | SKCM | 1 |
| p.E218K | SKCM | 1 |
| p.Q164E | KIRC | 1 |
| p.S60C | CESC | 1 |
| p.S60P | GBM | 1 |
| p.E429K | SKCM | 1 |
| p.R445L | LUAD | 1 |
| p.R392* | LUAD | 1 |
| p.S175L | SKCM | 1 |
| p.S248L | UCEC | 1 |
| p.R246I | UCEC | 1 |
| p.S459I | STAD | 1 |
| p.D273N | STAD | 1 |
| p.L331V | LUAD | 1 |
| p.S385L | BLCA | 1 |
| p.E125D | UCEC | 1 |
| p.R129S | STAD | 1 |
| p.R392Q | LUAD | 1 |
| Top |
| TissGeneCNV for ZNF165 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for ZNF165 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for ZNF165 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (tumor) | ZNF165, DVL2, ZNF250, TCEB3B, KRTAP4-12, EWSR1, SCAND1, CCDC85B, ZNF446, ZNF24, PDLIM7, FAM124A, CCDC130 (normal) |
 |  |
| Top |
| TissGeneProg for ZNF165 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for ZNF165 |
| TissGeneDrug for ZNF165 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for ZNF165 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0005684 | Malignant neoplasm of urinary bladder | 1 | BeFree |
| umls:C0007138 | Carcinoma, Transitional Cell | 1 | BeFree |
| umls:C0279680 | Transitional cell carcinoma of bladder | 1 | BeFree |
| umls:C0699885 | Carcinoma of bladder | 1 | BeFree |
| umls:C1704272 | Benign Prostatic Hyperplasia | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |